Yarrow Bioscience Inc (YARW) Stock Analysis & Investment Frameworks
Yarrow Bioscience Inc (YARW) stock analysis on Invetso. Review Yarrow Bioscience Inc’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Yarrow Bioscience Inc Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Yarrow Bioscience Inc Key Financial Metrics
- Market Cap: $462572.00
- Revenue: $570000.00
- ROE: -70.23%
- ROIC: -90.33%
- Dividend Yield: 74.72%
About Yarrow Bioscience Inc
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
Yarrow Bioscience Inc Investment Frameworks
Invetso analyzes Yarrow Bioscience Inc (YARW) across the following frameworks:
- Yarrow Bioscience Inc 10Y Growth Potential
- Yarrow Bioscience Inc Scenario Analysis
- Yarrow Bioscience Inc Risks & Opportunities
- Yarrow Bioscience Inc Economic Moat
- Yarrow Bioscience Inc Business Model
- Yarrow Bioscience Inc Management
- Yarrow Bioscience Inc SWOT Analysis
- Yarrow Bioscience Inc Porter's 5 Forces
- Yarrow Bioscience Inc PESTLE Analysis
- Yarrow Bioscience Inc ESG Analysis
